<DOC>
	<DOCNO>NCT01040780</DOCNO>
	<brief_summary>The purpose study determine whether Icotinib least non-inferior Gefitinib treatment advance non-small cell lung cancer ( NSCLC ) patient one two chemotherapy .</brief_summary>
	<brief_title>Safety Efficacy Study Icotinb Non-small Cell Lung Cancer ( NSCLC ) Patients</brief_title>
	<detailed_description>Lung cancer rapidest increase type cancer China 5 time incidence rate increase past 30 year . It lead cause death cancer man 2nd woman . With development gefitinib erlotinib , EGFR-TKI ( epidermal growth factor receptor -tyrosine kinase inhibitor ) successful novel drug develop treatment patient recent year , especially NSCLC patient Asia include China . Icotinib novel EGFR-TKI develop group Chinese scientist clinician . It appear least good gefitinib term efficacy good term safety phase I/II trial . In study , randomize , double-blind , gefitinib control , multi-center phase III trial design evaluate safety efficacy icotinib treatment advance NSCLC patient failure 1 2 chemotherapy . PFS ( progress free survival ) primary end-point OS ( overall survival ) , ORR ( objective response ) , TTP ( time progress ) , HRQOL safety secondary end-point . A total 400 patient recruit . EGFR K-ras gene mutational analysis well population PK study also propose .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>1 . Confirmed NSCLC Histology cytology ; advanced ï¼ˆIIIb/IV ) . 2 . Must receive 1 2 chemotherapy ( least 1 platin base ) , prior chemotherapy must complete least 4 week study enrollment ; = . 1 . Previous usage EGFRTKI antibody EGFR : gefitinib , erlotinib , herceptin , erbitux .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>EGFR-TKI</keyword>
	<keyword>phase III</keyword>
	<keyword>NSCLC</keyword>
</DOC>